ALCLS Cellectis SA

Calyxt Names Joseph B. Saluri as General Counsel & EVP, Corporate Development

Regulatory News:

Calyxt, Inc. (Paris:ALCLS) (NASDAQ:CLLS), a Minnesota-based company developing healthier specialty food ingredients to benefit both consumers and farmers, has named Joseph B. Saluri as General Counsel and Executive Vice President, Corporate Development. Mr. Saluri brings to Calyxt over 24 years of legal, business development, strategic planning and project management experience in the global agri-business space.

“We, at Calyxt, are thrilled to bring Joseph and his two-plus decades of experience in the ag-biotech and soybean technology spaces on board as General Counsel and EVP, Corporate Development,” said Federico Tripodi, Calyxt CEO. “We look forward to working with Joseph and utilizing his legal and regulatory expertise in the ag field, as we continue to expand our product portfolio and work toward commercializing our healthier food products.”

Mr. Saluri joins Calyxt from Stine Seed Company, where he spent 18 years serving as Chief Legal Officer and Vice President of Business Development. While serving as Chief Legal Officer at Stine, Mr. Saluri was responsible for all legal matters for the company and its related entities and oversaw all litigation, licensing, intellectual property, acquisitions, compliance and regulatory matters. In addition, Mr. Saluri advised on investment and business development opportunities and negotiated and acquired numerous breeding programs, seed trait technologies and retail seed businesses. He also managed Stine’s collaborations with several multi-national ag-biotech corporations, including strategy, research and development, global regulatory planning, execution and product launch.

"Calyxt is an innovator in the ag biotech industry that is simultaneously working to develop crops that meet the sustainability needs of an ever-changing global environment and the demands of consumers who want healthier food products," added Mr. Saluri. "I'm honored to join the team and look forward to capitalizing on my experiences to support the Company’s continued efforts to launch its commercial products."

Kincannon & Reed, a leading executive search firm focused on the food, agribusiness and biosciences sectors, assisted Calyxt in the recruitment of Joseph Saluri.

About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. By combining its leading gene-editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance, for farmers. Calyxt is located in Minneapolis-St. Paul, Minn., and is a wholly owned subsidiary of Cellectis.

For further information please visit our website: www.calyxt.com

Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.

Talking about gene editing? We do it.

TALEN® is a registered trademark owned by the Cellectis Group.

###

EN
07/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights01/31/2026100,590,994105,825,481 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur S...

 PRESS RELEASE

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/01/2026100 590 994105 825 481 Pour de plus amples informations sur Cellectis, veuillez contacter : Contacts média : Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of...

 PRESS RELEASE

Cellectis Announces 2026 Strategy and Catalysts

Cellectis Announces 2026 Strategy and Catalysts NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026. “2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel.” said André Choulika, Ph.D., Chief Executive ...

 PRESS RELEASE

Cellectis annonce sa stratégie et ses jalons attendus en 2026

Cellectis annonce sa stratégie et ses jalons attendus en 2026 NEW YORK, 08 janv. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies innovantes pour le traitement de maladies graves, présente aujourd'hui ses priorités stratégiques et les principaux jalons attendus en 2026. « 2025 a marqué un tournant stratégique pour Cellectis : nous avons franchi une étape majeure en devenant une société de biotechnologie au stade cli...

 PRESS RELEASE

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 janv. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/12/2025100 339 441105 576 356    Pour de plus amples informations sur Cellectis, veuillez contacter :         Contacts média :         Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa N...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch